AstraZeneca and Regeneron to research, develop and commercialise new small molecule medicines for obesity

Novel small molecule drug candidates will target GPR75 to potentially address obesity and related co-morbidities

29-Jul-2021 - AstraZeneca has entered into a collaboration with Regeneron to research, develop and commercialise small molecule compounds directed against the GPR75 target with the potential to treat obesity and related co-morbidities. The companies will evenly split research and development costs and share ...

Sanofi and Regeneron Launch Major New Immuno-Oncology Collaboration

Companies agree to jointly advance PD-1 and other new immuno-oncology antibodies

29-Jul-2015 - Sanofi and Regeneron Pharmaceuticals, Inc. have entered into a new global collaboration to discover, develop and commercialize new antibody cancer treatments in the emerging field of immuno-oncology. As part of the agreement, the two companies will jointly develop a programmed cell death protein ...

Sanofi and Regeneron Announce New Results from Six Phase 3 Trials Showing that Alirocumab Significantly Reduced LDL Cholesterol

21-Nov-2014 - Sanofi and Regeneron Pharmaceuticals, Inc. announced new detailed positive results from six Phase 3 ODYSSEY trials that showed alirocumab significantly reduced low-density lipoprotein cholesterol (LDL-C, or "bad" cholesterol). Alirocumab is an investigational fully human monoclonal antibody ...

Sanofi and Regeneron Announce Start of Phase 3 Study of Dupilumab in Patients with Atopic Dermatitis

21-Oct-2014 - Sanofi and Regeneron Pharmaceuticals, Inc. announced that the first patients have been dosed in a Phase 3 clinical study of dupilumab, an investigational therapy that blocks IL-4 and IL-13 signaling, in adults with moderate-to-severe atopic dermatitis (AD) that is not adequately controlled with ...

Sanofi-aventis and Regeneron expand strategic Antibody Collaboration

Collaboration goal is to advance 4 to 5 antibodies per year into clinical development

13-Nov-2009 - Sanofi-aventis and Regeneron Pharmaceuticals, Inc. announced that they have entered into agreements to expand and extend their existing global collaboration to discover, develop, and commercialize fully-human therapeutic monoclonal antibodies. Sanofi-aventis will increase its annual funding ...

Bayer HealthCare: positive phase 2 results for the VEGF Trap-Eye

02-Oct-2007 - Bayer HealthCare and development partner Regeneron Pharmaceuticals, Inc. announced positive results from a Phase 2 study evaluating the VEGF Trap-Eye in the neovascular form of age-related macular degeneration (wet AMD), one of the leading causes of blindness in adults. The VEGF Trap-Eye met both ...

Phase-II-Studie für VEGF Trap-Eye zeigt positive Zwischenergebnisse bei altersbedingter Makula-Degeneration

Bayer HealthCare und Regeneron planen Start einer Phase-III-Studie im zweiten Halbjahr 2007

29-Mar-2007 - Positive Ergebnisse zeigt die vorläufige Zwischenanalyse einer Phase-II-Studie mit VEGF Trap-Eye. Die Studie untersucht VEGF Trap-Eye zur Behandlung einer Form der feuchten altersbedingten Makula-Degeneration (AMD). Die Patienten wurden in fünf Gruppen unterteilt und erhielten verschiedene ...

Regeneron And Aventis Begin Study Of Intravenous VEGF Trap In Cancer

16-Apr-2004 - Tarrytown, New York - Regeneron Pharmaceuticals, Inc. announced the initiation of a Phase I Clinical Trial in cancer to assess the safety and tolerability of intravenous VEGF Trap. The study is being conducted in collaboration with Aventis, Regeneron's partner in the development of the VEGF Trap ...

Regeneron To Receive 42.75 Million From Novartis To Satisfy Novartis' Remaining Funding Obligation For Development Of The IL-1 T

Regeneron Also Achieves Development Milestone, Resulting In Loan Forgiveness

05-Apr-2004 - Tarrytown, NY. Regeneron Pharmaceuticals, Inc. announced that Novartis Pharma AG has agreed to pay Regeneron $42.75 million to satisfy its obligation to fund development costs for the Interleukin-1 (IL-1) Trap for the nine month period following notification of Novartis' decision to forgo its ...